综合一区欧美国产,99国产麻豆免费精品,九九精品黄色录像,亚洲激情青青草,久久亚洲熟妇熟,中文字幕av在线播放,国产一区二区卡,九九久久国产精品,久久精品视频免费

Business / Baby formula

China's mums key to Nestle baby milk deal

(Agencies) Updated: 2012-04-25 11:19

LONDON/BEIJING - The rise of the middle-class Chinese working mothers helps explain why Nestle paid nearly $12 billion for Pfizer's baby food business and could leave rivals scrambling to catch up.

Across emerging markets, nowhere more than in China, women are increasingly keeping jobs after having children -- a big driving force behind 10 percent annual growth in the $30 billion a year baby food industry.

Foreign labels such as SMA, Promil and S-26 Gold, which Nestle will get with the Pfizer deal, have a definite edge. Nestle's products include Nan, Gerber, Lactogen and Nestogen, but are less well known in China.

Baby milk was the foundation of the world's biggest food company, established in 1866 when German pharmacist Henri Nestle introduced a substitute for mothers who could not breast-feed.

Paying more for the Pfizer unit than the $10 billion that analysts had expected, Nestle trumped a bid from Danone and Mead Johnson.

The Pfizer nutrition business has 85 percent of its sales in emerging markets, and a quarter of sales in China.

Fuelled by 16 million new births a year, annual growth rates for China's baby formula market have been as high as 20 percent over the last five years. The market is forecast to double to $16 billion by 2016.

"The key strategic attraction of the deal in our view is Pfizer's No 5 position in the Chinese infant formula market where despite being global No 1 player in infant formula, Nestle has a relatively weak presence," said analyst Robert Dickinson at brokers Citi.

The Swiss giant is already market leader in milk formula in Latin America, Africa and the Middle East. This brings it the No 1 spot in Asia with its presence outside China counted too.

Globally, Nestle's baby food market share will rise to 25 percent from 19 percent - although this is likely to fall slightly after sell-offs to ensure regulatory clearance. Mead has 16 percent, Danone 14 percent and Abbott Laboratories 12 percent.

Few options for competitors

The Nestle-Pfizer business in China would only have a combined 12 percent market share behind Mead's leading 16 percent and Danone on 14 percent, but that would still be a rise from 10th place and there may be room for expansion.

Analysts looking at China expect the number of middle class households to double to 100 million by 2015.

Hot Topics

Editor's Picks
...
呈贡县| 革吉县| 新密市| 台东县| 金溪县| 紫云| 微山县| 平阴县| 衢州市| 广州市| 龙山县| 伊川县| 洞头县| 临泽县| 体育| 洪泽县| 怀集县| 荃湾区| 家居| 宜兴市| 武城县| 商水县| 惠来县| 马关县| 石柱| 泾川县| 惠来县| 禹州市| 东台市| 平泉县| 吴堡县| 铜陵市| 特克斯县| 清河县| 武鸣县| 承德市| 迁西县| 治多县| 马关县| 大悟县| 开鲁县|